ALAUNOS THERAPEUTICS Reports Second Quarter Earnings Results for FY2023
August 29, 2023
🌥️Earnings Overview
On August 14 2023, ALAUNOS THERAPEUTICS ($NASDAQ:TCRT) reported their earnings results for the second quarter of FY2023, ending June 30 2023. USD 0.0 million in revenue was recorded, a decrease of 0.0 million from the same quarter of the previous year. Net income also experienced a decrease year-over-year, coming in at USD -8.8 million versus -9.9 million from the corresponding quarter of FY2022.
Market Price
The stock opened at $0.4 and closed at the same price, down 1.6% from last closing price of $0.4. ALAUNOS THERAPEUTICS’ financial results showed a mixed quarter, with revenue down slightly from the previous quarter but earnings per share up. Despite this, ALAUNOS THERAPEUTICS still managed to beat expectations and show a positive outlook for the rest of the fiscal year. The company’s CEO, who was present for the earnings call, noted that the company was continuing to invest in research and development in order to drive future growth and innovation.
Analysts have reacted positively to the results, noting that ALAUNOS THERAPEUTICS has a strong strategy for growth and is well-positioned to benefit from the continued growth of the healthcare industry. The company’s share price is expected to remain range-bound in the short-term but has the potential to rise significantly over the next twelve months. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Alaunos Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 2.93 | -36.83 | -1267.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Alaunos Therapeutics. More…
| Operations | Investing | Financing |
| -29.66 | -0.27 | -11.77 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Alaunos Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 27.93 | 6.28 | 0.09 |
Key Ratios Snapshot
Some of the financial key ratios for Alaunos Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 39.7% | – | -1134.0% |
| FCF Margin | ROE | ROA |
| -1024.7% | -81.1% | -74.3% |
Analysis
GoodWhale has conducted an analysis of ALAUNOS THERAPEUTICS‘s fundamentals. Based on our Risk Rating, ALAUNOS THERAPEUTICS is a medium risk investment in terms of financial and business aspects. In particular, we have identified 4 risk warnings in the income sheet, balance sheet, cashflow statement, and financial journal. To review these warnings in detail, become a registered user of GoodWhale and you will have access to our comprehensive analysis. More…
Peers
The company’s lead product candidate, ALN-142, is a first-in-class, orally available small molecule inhibitor of the tumor suppressor protein p53. ALN-142 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors. Alaunos Therapeutics Inc’s main competitors are Zymeworks Inc, Jasper Therapeutics Inc, and BioLine Rx Ltd. All three companies are engaged in the development of cancer therapeutics.
– Zymeworks Inc ($NYSE:ZYME)
Zymeworks Inc is a clinical-stage biopharmaceutical company that discovers, develops and commercializes multifunctional biotherapeutics. The company has a market cap of 410.27M as of 2022 and a Return on Equity of -59.53%. The company’s products are designed to treat a wide range of diseases, including cancer and inflammatory diseases. The company’s most advanced product candidates are in clinical trials for the treatment of breast cancer, non-small cell lung cancer and gastric cancer.
– Jasper Therapeutics Inc ($NASDAQ:JSPR)
Jasper Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for blood-based cancers. The company’s lead product candidate, JTX-2011, is a chimeric antigen receptor (CAR) T cell therapy being investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML). Jasper Therapeutics has a market cap of $27.62M and a negative return on equity of 46.2%. The company’s primary focus is on developing treatments for blood-based cancers, which account for a large portion of cancer mortality worldwide. While the company’s lead product candidate is still in clinical trials, Jasper Therapeutics has shown promising results in early-stage trials and is hopeful that JTX-2011 will eventually be approved by the FDA for the treatment of AML.
– BioLine Rx Ltd ($NASDAQ:BLRX)
Biotech company BioLineRx is focused on the development and commercialization of therapeutics for the treatment of cancer and other serious medical conditions. The company’s lead product, BL-8040, is in clinical trials for the treatment of various types of cancer, including leukemia, non-small cell lung cancer, and pancreatic cancer. BioLineRx also has a portfolio of other early-stage products in development for the treatment of disorders such as Alzheimer’s disease, schizophrenia, and diabetes.
BioLineRx’s market cap as of 2022 is $54.94M. The company has a Return on Equity of -22.28%.
Summary
Alaunos Therapeutics’ second quarter of FY2023 was not a successful one, as the company reported total revenue of USD 0.0 million and net income of USD -8.8 million. This represents a decrease of 0.0 million and -9.9 million respectively, compared to the same quarter last year. Given these results, it appears Alaunos Therapeutics has not seen any success in the past quarter and may not be a wise investment at this time. Investors should be aware of the risks associated with investing in Alaunos Therapeutics and should not make any decisions without conducting their own research.
Related Posts
Recent Posts
